What is the current stock price of Axsome Therapeutics, Inc. (AXSM)?

As of the latest market data, Axsome Therapeutics, Inc. (AXSM) is trading at $178.11. The stock has seen a loss of -0.44% today.

Does Axsome Therapeutics, Inc. (AXSM) pay a dividend?

Based on current data, Axsome Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Axsome Therapeutics, Inc.?

The current market capitalization of Axsome Therapeutics, Inc. (AXSM) is approximately unavailable.

AXSM

Axsome Therapeutics, Inc.·Healthcare

178.11

0.442%(−0.79)

Market Closed

179.29

0.663%(+1.18)

After Hours

Last Updated: — ET

52W L: $96.0952W H: $191.50

AXSM NEWS

defenseworld.net

1d ago

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of “Moderate Buy” by Brokerages

Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, seventeen have assigned a buy rating and one has given a strong buy rating to

fool.com

2d ago

Is This Healthcare Stock a Millionaire Maker?

Axsome Therapeutics has performed well since its IPO. The company's current lineup and pipeline could drive growth for a while.

globenewswire.com

3d ago

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2026 on Monday, May 4, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

defenseworld.net

Apr 4

SG Americas Securities LLC Acquires 5,584 Shares of Axsome Therapeutics, Inc. $AXSM

SG Americas Securities LLC lifted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 46.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,681 shares of the company's stock after purchasing an additional 5,584 shares during the period.

fool.com

Mar 25

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now

Summit Therapeutics shares could drop later this year if it doesn't earn approval for its leading candidate. Madrigal Pharmaceuticals and Axsome Therapeutics could move in the opposite direction.

zacks.com

Mar 25

Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

712

IPO Date

2015-11-19

Beta

0.47

Websitewww.axsome.com↗